n-n-dimethyl-n-(18f)fluoromethyl-2-hydroxyethylammonium has been researched along with alovudine* in 1 studies
1 other study(ies) available for n-n-dimethyl-n-(18f)fluoromethyl-2-hydroxyethylammonium and alovudine
| Article | Year |
|---|---|
ORGAN DOSES AND EFFECTIVE DOSE FOR FIVE PET RADIOPHARMACEUTICALS.
Diagnostic investigations with positron-emitting radiopharmaceuticals are dominated by (18)F-fluorodeoxyglucose ((18)F-FDG), but other radiopharmaceuticals are also commercially available or under development. Five of them, which are all clinically important, are (18)F-fluoride, (18)F-fluoroethyltyrosine ((18)F-FET), (18)F-deoxyfluorothymidine ((18)F-FLT), (18)F-fluorocholine ((18)F-choline) and (11)C-raclopride. To estimate the potential risk of stochastic effects (mainly lethal cancer) to a population, organ doses and effective dose values were updated for all five radiopharmaceuticals. Dose calculations were performed using the computer program IDAC2.0, which bases its calculations on the ICRP/ICRU adult reference voxel phantoms and the tissue weighting factors from ICRP publication 103. The biokinetic models were taken from ICRP publication 128. For organ doses, there are substantial changes. The only significant change in effective dose compared with previous estimations was a 46 % reduction for (18)F-fluoride. The estimated effective dose in mSv MBq(-1) was 1.5E-02 for (18)F-FET, 1.5E-02 for (18)F-FLT, 2.0E-02 for (18)F-choline, 9.0E-03 for (18)F-fluoride and 4.4E-03 for (11)C-raclopride. Topics: Carbon Isotopes; Choline; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Kinetics; Male; Phantoms, Imaging; Positron-Emission Tomography; Raclopride; Radiation Dosage; Radiometry; Radiopharmaceuticals; Software; Stochastic Processes; Tyrosine | 2016 |